You may want to consider the following article where novartis missed their primary endpoint and yet the FDA are trying to approve their treatment. They have their committee meeting tonight, which i will try to watch with interest. Since this is heart disease, the FDA will likely not apply their usual high bar to these results.
https://www.fiercepharma.com/marketing/where-do-you-stand-fda-reviewers-argue-for-novartis-entresto-committee-meeting-file
Even if we only get accelerated approval, reimbursement won't be too hard to come by. This is heart disease after all.
You may want to consider the following article where novartis...
-
- There are more pages in this discussion • 826 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |